Citations

Showing 10 of 108094 citations.

Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib
Tefferi, Ayalew , Pardanani, Animesh , Begna, Kebede H. , Al‐Kali, Aref , Litzow, Mark R. , Hanson, Curtis A. , Gangat, Naseema , Litzow, Mark R. , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | September 4, 2022 | Volume: 97 | Issue: 12 | Pages: No page available

10.1002/ajh.26714 | PMID 36057774 Get It

Jaktinib (JAK1/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule
Tefferi, Ayalew , Gangat, Naseema , Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | September 4, 2022 | Volume: 97 | Issue: 12 | Pages: 1507-1509

10.1002/ajh.26712 | PMID 36057765 Get It

Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma
Alderuccio, Juan Pablo , Habermann, Thomas M. , Link, Brian K. , Thiéblemont, Catherine , Conconi, Annarita , Zhao, Wei , Cerhan, James R. , Lossos, Izidore S. , Habermann, Thomas , Cerhan, James R , Lossos, Izidore S , Link, Brian K , Reis, Isildinha Marques dos , Larson, Melissa C. , Cascione, Luciano , Zucca, Emanuele

Mayo Clinic

American Journal of Hematology | September 3, 2022 | Volume: 97 | Issue: 12 | Pages: 1529-1537

10.1002/ajh.26715 | PMID 36057138 Get It

AbstractExtranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression‐free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the “Revised mucosa‐associated lymphoid tissue International Prognostic Index” (Revised MALT‐IPI) in a large data set (n = 397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT‐IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n = 297) and from IELSG‐19 study (n = 400). A stepwise Cox regression analysis yielded a model including four independent predictors of shorter PFS. Revised MALT‐IPI has scores ranging from 0 to 5, calculated as a sum of one point for each of the following‐ age >60 years, elevated LDH, and stage III–IV; and two points for MMS. In the training cohort, the Revised MALT‐IPI defined four risk groups: low risk (score 0, reference group), low‐medium risk (score 1, HR = 1.85, p = .008), medium‐high risk (score 2, HR = 3.84, p < .0001), and high risk (score 3+, HR = 8.48, p < .0001). Performance of the Revised MALT‐IPI was similar in external validation cohorts. Revised MALT‐IPI is a new index centered on disease characteristics that provides robust risk‐stratification identifying a group of patients characterized by earlier progression of disease. Revised MALT‐IPI can allow a more disease‐adjusted management of patients with EMZL in clinical trials and practice.
Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Grant, Leah , Orenstein, Robert , Grant, Leah M

Mayo Clinic

Journal of Investigative Medicine High Impact Case Reports | September 3, 2022 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/23247096221123144 | PMID 36059275 Get It

Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.
IDDF2022-ABS-0084 Adar1-mediated RNA editing of scd1 links lipid metabolism to drug resistance and self-renewal in gastric cancer
Loh, Jia-Jian, Lu, Shi‐Xun, Yan, Helen HN, Siu, Hoi-Cheong, Chan, Dessy , Kam, Max JF, Copland, John A. , Chan, Leilei, Ren, Xi , Yun, Jing‐Ping , Leung, Suet-Yi, Wong, Tin Lok , Siu, Hoi Cheong , Zhou, Lei , Tong, Man , Leung, Suet-Yi

Mayo Clinic

Basic Gastroenterology | September 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A45.1-A45

10.1136/gutjnl-2022-iddf.47 Get It

Analysis of College of American Pathologists von Willebrand Factor Proficiency Testing Program
Salazar, Eric , Long, Thomas A., Smock, Kristi J. , Chen, Dong , Harris, Neil Selwyn, Olson, John D. , Ritter, Jacob, Unold, David, VanSandt, Amanda M., Goodwin, Andrew , Chen, Dong , Wool, Geoffrey D. , Rollins‐Raval, Marian A. , Harris, Neil Selwyn, Chan, Clarence W. , Pham, Huy P.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | September 2, 2022 | Volume: 48 | Issue: 06 | Pages: 690-699

10.1055/s-0042-1749591 | PMID 36055272 Get It

AbstractVon Willebrand factor (VWF) level and/or function is altered in von Willebrand disease (VWD), the most common heritable bleeding disorder worldwide. Laboratory assessment of VWF is continually evolving. Historically, the primary method for the assessment of VWF platelet-binding activity was the ristocetin cofactor assay (VWF:RCo). Contemporary alternative measures of VWF platelet-binding activity include VWF:GPIbR (recombinant; using ristocetin), VWF:GPIbM (recombinant; gain-of-function mutant), and monoclonal antibody. Recently, the American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia collaboration issued guidelines recommending the use of newer assays of VWF platelet-binding activity (VWF: GPIbM, VWF: GPIbR) over VWF:RCo, given known limitations of the VWF:RCo assay. Despite this recommendation, the newer VWF:GPIbM and VWF:GPIbR assays are not United States Food and Drug Administration cleared, limiting their availability in the United States. We sought to assess assay utilization trends, agreement of VWF testing methods, and imprecision of VWF testing (based on assigned sample type) from the College of American Pathologists Proficiency Testing Surveys. The analysis confirms that, while VWF antigen testing has low imprecision, the various VWF activity assays have significant interassay variability, with VWF:RCo showing greater imprecision than the newer GPIb-binding assays. The overall trends in assay utilization reflect the barriers to complete compliance with modern VWD diagnostic guidelines in North America.
Volumetric Pancreas Segmentation on Computed Tomography: Accuracy and Efficiency of a Convolutional Neural Network Versus Manual Segmentation in 3D Slicer in the Context of Interreader Variability of Expert Radiologists
Khasawneh, Hala , Patra, Anurima , Rajamohan, Naveen , Suman, Garima , Klug, Jason R., Majumder, Shounak , Korfiatis, Panagiotis , Goenka, Ajit H. , Klug, Jason, Goenka, Ajit Harishkumar, Majumder, Shounak , Khasawneh, Hala , Chari, Suresh T.

Mayo Clinic

Journal of Computer Assisted Tomography | September 2, 2022 | Volume: 46 | Issue: 6 | Pages: 841-847

10.1097/rct.0000000000001374 | PMID 36055122 Get It

Purpose This study aimed to compare accuracy and efficiency of a convolutional neural network (CNN)–enhanced workflow for pancreas segmentation versus radiologists in the context of interreader reliability. Methods Volumetric pancreas segmentations on a data set of 294 portal venous computed tomographies were performed by 3 radiologists (R1, R2, and R3) and by a CNN. Convolutional neural network segmentations were reviewed and, if needed, corrected (“corrected CNN [c-CNN]” segmentations) by radiologists. Ground truth was obtained from radiologists' manual segmentations using simultaneous truth and performance level estimation algorithm. Interreader reliability and model's accuracy were evaluated with Dice-Sorenson coefficient (DSC) and Jaccard coefficient (JC). Equivalence was determined using a two 1-sided test. Convolutional neural network segmentations below the 25th percentile DSC were reviewed to evaluate segmentation errors. Time for manual segmentation and c-CNN was compared. Results Pancreas volumes from 3 sets of segmentations (manual, CNN, and c-CNN) were noninferior to simultaneous truth and performance level estimation–derived volumes [76.6 cm3 (20.2 cm3), P < 0.05]. Interreader reliability was high (mean [SD] DSC between R2-R1, 0.87 [0.04]; R3-R1, 0.90 [0.05]; R2-R3, 0.87 [0.04]). Convolutional neural network segmentations were highly accurate (DSC, 0.88 [0.05]; JC, 0.79 [0.07]) and required minimal-to-no corrections (c-CNN: DSC, 0.89 [0.04]; JC, 0.81 [0.06]; equivalence, P < 0.05). Undersegmentation (n = 47 [64%]) was common in the 73 CNN segmentations below 25th percentile DSC, but there were no major errors. Total inference time (minutes) for CNN was 1.2 (0.3). Average time (minutes) taken by radiologists for c-CNN (0.6 [0.97]) was substantially lower compared with manual segmentation (3.37 [1.47]; savings of 77.9%–87% [P < 0.0001]). Conclusions Convolutional neural network–enhanced workflow provides high accuracy and efficiency for volumetric pancreas segmentation on computed tomography.
Articular Findings on Chest Computed Tomography: An Algorithmic Approach for Radiologists
Mansoori, Bahar , Kosaraju, Vijaya, Yoon, James, Zadeh, Firoozeh Shomal , Vo, Kiet V. , Shafiei, Mehrzad , Rajiah, Prabhakar , Rajiah, Prabhakar , Chalian, Hamid , Chalian, Majid

Mayo Clinic

Journal of Computer Assisted Tomography | September 2, 2022 | Volume: 46 | Issue: 6 | Pages: 914-922

10.1097/rct.0000000000001364 | PMID 36055107 Get It

Abstract Chest computed tomography (CT) is one of the most frequently performed imaging studies. Incidental osseous and articular findings are commonly encountered in chest CTs in daily practice. The spectrum of findings is broad, varying from benign to malignant, and interpretation of these incidental musculoskeletal findings could be challenging for radiologists. In this review, we provide a systematic algorithmic approach for the diagnosis of common articular findings seen on chest CT with recommendations for appropriate follow-up evaluation.
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
Roth, Michael , Parsons, Susan K. , Ganz, Patricia A. , Wagner, Lynne I. , Alexander, Sarah , Bingen, Kristin , Cella, David , Henry, N. Lynn , Indelicato, Daniel J. , Johnson, Rebecca H. , Miller, Tamara P. , Rosenberg, Shoshana M. , Thanarajasingam, Gita , Roth, Michael E , Thanarajasingam, Gita , Reeve, Bryce B. , Salsman, John M , Wagner, Lynne , Henry, N Lynn , K Parsons, Susan , Indelicato, Daniel J , Hinds, Pamela S. , Bober, Sharon L. , Brackett, Julienne , Schmitz, Kathryn H.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 2, 2022 | Volume: 115 | Issue: 1 | Pages: 21-28

10.1093/jnci/djac166 | PMID 36266760 Get It

Abstract Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported outcomes (PROs) in cancer clinical trials (CCTs). The AYA years include key developmental milestones distinct from younger and older patients, and cancer interrupts attainment of critical life goals. Lack of consensus on a standardized approach to assess HRQoL and treatment-related toxicity in AYA CCTs has limited the ability to improve patient outcomes. The National Cancer Institute’s Clinical Trials Network AYA PRO Task Force was assembled to reach consensus on a core set of PROs and foster its integration into AYA CCTs. Eight key considerations for selecting the core PRO AYA battery components were identified: relevance to AYAs; importance of constructs across the age continuum; prioritization of validated measures; availability of measures without licensing fees; availability in multiple languages; applicability to different cancer types and treatments; ability to measure different HRQoL domains and toxicities; and minimized burden on patients and sites. The Task Force used a modified Delphi approach to identify key components of the PRO battery. The Patient-Reported Outcomes Measurement Information System (PROMIS) and the PRO Common Terminology Criteria for Adverse Events Measurement System met all criteria and were selected to assess HRQoL and treatment toxicity, respectively. Investigators are rapidly incorporating the recommendations of the Task Force into AYA trials. Inclusion of a standardized assessment of HRQoL and treatment toxicities in AYA CCTs is a vital first step to develop interventions to improve health outcomes for AYAs diagnosed with cancer.
Effect of a Condensed NBA Season on Injury Risk: An Analysis of the 2020 Season and Player Safety
Morikawa, Landon , Brinkman, Joseph C. , Petty, Skye A. Buckner, Buckner Petty, Skye A, Tummala, Sailesh V , Tummala, Sailesh V. , Chhabra, Anikar

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 2, 2022 | Volume: 10 | Issue: 9 | Pages: No page available

10.1177/23259671221121116 | PMID 36081413 Get It

Background: Health and safety concerns surrounding the coronavirus 2019 (COVID-19) pandemic led the National Basketball Association (NBA) to condense and accelerate the 2020 season. Although prior literature has suggested that inadequate rest may lead to an increased injury risk, the unique circumstances surrounding this season offer a unique opportunity to evaluate player safety in the setting of reduced interval rest. Hypothesis: We hypothesized that the condensed 2020 NBA season resulted in an increased overall injury risk as compared with the 2015 to 2018 seasons. Study Design: Descriptive epidemiology study. Methods: A publicly available database, Pro Sports Transactions, was queried for injuries that forced players to miss ≥1 game between the 2015 and 2020 seasons. Data from the 2019 season were omitted given the abrupt suspension of the league year. All injury incidences were calculated per 1000 game-exposures (GEs). The primary outcome was the overall injury proportion ratio (IPR) between the 2020 season and previous seasons. Secondary measures included injury incidences stratified by type, severity, age, position, and minutes per game. Results: A total of 4346 injuries occurred over a 5-season span among 2572 unique player-seasons. The overall incidence of injury during the 2020 season was 48.20 per 1000 GEs but decreased to 39.97 per 1000 GEs when excluding COVID-19. Despite this exclusion, the overall injury rate in 2020 remained significantly greater (IPR, 1.42 [95% CI, 1.32-1.52]) than that of the 2015 to 2018 seasons (28.20 per 1000 GEs). On closer evaluation, the most notable increases seen in the 2020 season occurred within minor injuries requiring only a 1-game absence (IPR, 1.53 [95% CI, 1.37-1.70]) and in players who were aged 25 to 29 years (IPR, 1.57 [95% CI, 1.40-2.63]), averaging ≥30.0 minutes per game (IPR, 1.67 [95% CI, 1.47-1.90]), and playing the point guard position (IPR, 1.67 [95% 1.44-1.95]). Conclusion: Players in the condensed 2020 NBA season had a significantly higher incidence of injuries when compared with the prior 4 seasons, even when excluding COVID-19–related absences. This rise is consistent with the other congested NBA seasons of 1998 and 2011. These findings suggest that condensing the NBA schedule is associated with an increased risk to player health and safety.